# Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

> **NCT01256398** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

## Interventions

- **BIOLOGICAL:** Alemtuzumab
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dasatinib
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide Phosphate
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Fludarabine Phosphate
- **PROCEDURE:** In Vitro-Treated Peripheral Blood Stem Cell Transplantation
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Melphalan
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Pegfilgrastim
- **OTHER:** Pharmacological Study
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01256398
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-14
- **Primary completion:** 2017-11-14
- **Final completion:** 2021-11-15
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256398, "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01256398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*